Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Tailin BioEngineering Co.,Ltd (300813.SZ)
Hangzhou, AH, CN
Zhejiang Tailin BioEngineering Co.,Ltd offers life science system solutions in China. The company offers cell and gene therapy solutions, including biosafety ferret isolators, sterile pig preparation solutions, aseptic filling workstation, cell preparation workstation, and robotic packaging workstations; drug development and sterile production solutions, comprising sterile packaging, highly active drug development/production, aseptic material transfer, packaging and test equipment, automated production solutions, sterility tests, and sterile connectors; microbiological detection systems; sterility testing systems; biodecontamination and infection control solutions; analytical instruments; quality control solutions, and laboratory animals/scientific research products, as well as active microbial products, and membrane materials. Its products are used in bio-pharmaceuticals, biosafety, disease control, food safety, and other industries. Zhejiang Tailin BioEngineering Co.,Ltd was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. The company was founded in 1993 and is based in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.08% | -10.45% | -16.43% | -17.81% | -19.38% | -12.82% | +11.27% | -27.85% | -1.43% | +29.74% | +29.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Consumer Electronics: +7.8%-4.2% Q1'26: +3.6% (vs Q1'25)
-
EPS growth Consumer Electronics: +23.0%+16.7% Q1'26: +33.0% (vs Q1'25)
-
FCF margin FCF growth · Consumer Electronics: +37.3%+4.2% Q1'26: -17.8% (vs Q1'25)
-
EBIT margin Consumer Electronics: +5.7%+0.3% Q1'26: +4.6% (vs Q1'25)
-
ROIC Consumer Electronics: +4.9%+0.2% Q1'26: +2.0% (vs Q1'25)
-
Share dilution Consumer Electronics: +0.0%+11.4% Q1'26: +3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Consumer Electronics: -0.57×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Da Lin Ye | GM & Chairman | — | male |
| Wen Qin Zhou | Accounting Supervisor | — | — |
| Xiaolu Ni | General Manager of Tailin Life Sciences Division & Director | — | male |
| Xin Qun Xia | Deputy GM & Director | — | male |
| Xing Yue Ye | Chief Financial Officer & Secretary of the Board | — | male |
| Zhi Lin Shen | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300813.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
